SCOPUS 정보 검색 플랫폼

Best Practice and Research: Clinical Haematology

Volumn 26, Issue 3, 2013, Pages 241-244

Important milestones in acute leukemia in 2013

(1) Rowe, Jacob M a,b,c,d

a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY (Israel)

b Department of Hematology ^* (Israel)

c NORTHWESTERN UNIVERSITY (United States)

d SHAARE ZEDEK MEDICAL CENTER (Israel)

Author keywords

acute leukemia forum; acute myeloid leukemia; AML; hematopoietic cell transplant

Indexed keywords

CYTARABINE; DAUNORUBICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVOR; CHROMOSOME 16; CHROMOSOME ABERRATION; CHROMOSOME INVERSION; CONTINUOUS INFUSION; CYTOGENETICS; DRUG INDUSTRY; DRUG MEGADOSE; GENE MUTATION; GENETIC HETEROGENEITY; GROUPS BY AGE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PRIORITY JOURNAL; TREATMENT RESPONSE;

7+3; ACUTE LEUKEMIA FORUM; ACUTE MYELOID LEUKEMIA; AML; HEMATOPOIETIC CELL TRANSPLANT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; DAUNORUBICIN; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; LEUKEMIA, MYELOID, ACUTE; MUTATION; NEOPLASM PROTEINS; REMISSION INDUCTION; SURVIVAL ANALYSIS;

EID: 84889632633 PISSN: 15216926 EISSN: 15321924 Source Type: Journal
DOI: 10.1016/j.beha.2013.10.002 Document Type: Review

Times cited : (14)

References (7)

1
- 0015721940
- Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia
- J.W. Yates, H.J. Wallace Jr., and R.R. Ellison Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia Cancer Chemother Rep 57 1973 485 488
- (1973) Cancer Chemother Rep , vol.57 , pp. 485-488
- Yates, J.W.¹ Wallace, Jr.H.J.² Ellison, R.R.³

2
- 84871989429
- A historical perspective on the development of the cytarabine (7days) and daunorubicin (3days) treatment regimen for acute myelogenous leukemia: 2013 the 40th anniversary of 7+3
- M.A. Lichtman A historical perspective on the development of the cytarabine (7days) and daunorubicin (3days) treatment regimen for acute myelogenous leukemia: 2013 the 40th anniversary of 7+3 Blood Cells Mol Dis 50 2013 119 130
- (2013) Blood Cells Mol Dis , vol.50 , pp. 119-130
- Lichtman, M.A.¹

3
- 70349467775
- Anthracycline dose intensification in acute myeloid leukemia
- H.F. Fernandez, Z. Sun, and X. Yao Anthracycline dose intensification in acute myeloid leukemia N Engl J Med 361 2009 1249 1259
- (2009) N Engl J Med , vol.361 , pp. 1249-1259
- Fernandez, H.F.¹ Sun, Z.² Yao, X.³

4
- 84889653934
- [accessed 01.30.13]
- Worldwide Network for Blood and Marrow Transplantation. 1 millionth blood stem cell transplant marks major medical milestone. http://www.worldmarrow.org/ fileadmin/Press-Releases/Press-release-final.pdf [accessed 01.30.13].
- Worldwide Network for Blood and Marrow Transplantation. 1 millionth blood stem cell transplant marks major medical milestone

5
- 84870708815
- The impact of mutational profiling on AML prognosis
- J.M. Rowe The impact of mutational profiling on AML prognosis Best Pract Res Clin Haematol 25 2012 403 408
- (2012) Best Pract Res Clin Haematol , vol.25 , pp. 403-408
- Rowe, J.M.¹

6
- 84872597896
- Genetic profiling in acute myeloid leukaemia-where are we and what is its role in patient management
- Y. Ofran, and J.M. Rowe Genetic profiling in acute myeloid leukaemia-where are we and what is its role in patient management Br J Haematol 160 2013 303 320
- (2013) Br J Haematol , vol.160 , pp. 303-320
- Ofran, Y.¹ Rowe, J.M.²

7
- 84872056078
- Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): A study of the German-Austrian AML Study Group (AMLSG)
- P. Paschka, J. Du, and R.F. Schlenk Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): A study of the German-Austrian AML Study Group (AMLSG) Blood 121 2013 170 177
- (2013) Blood , vol.121 , pp. 170-177
- Paschka, P.¹ Du, J.² Schlenk, R.F.³

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.